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Abstract
Given that the bioactive lipid sphingosine 1-phosphate is involved in cardiovascular pathophysiology, and since lipid
accumulation and inflammation are hallmarks of calcific aortic stenosis, the role of sphingosine 1-phosphate on the pro-
inflammatory/pro-osteogenic pathways in human interstitial cells from aortic and pulmonary valves was investigated. Real-
time PCR showed sphingosine 1-phosphate receptor expression in aortic valve interstitial cells. Exposure of cells to
sphingosine 1-phosphate induced pro-inflammatory responses characterized by interleukin-6, interleukin-8, and
cyclooxygenase-2 up-regulations, as observed by ELISA and Western blot. Strikingly, cell treatment with sphingosine 1-
phosphate plus lipopolysaccharide resulted in the synergistic induction of cyclooxygenase-2, and intercellular adhesion
molecule 1, as well as the secretion of prostaglandin E2, the soluble form of the intercellular adhesion molecule 1, and the
pro-angiogenic factor vascular endothelial growth factor-A. Remarkably, the synergistic effect was significantly higher in
aortic valve interstitial cells from stenotic than control valves, and was drastically lower in cells from pulmonary valves,
which rarely undergo stenosis. siRNA and pharmacological analysis revealed the involvement of sphingosine 1-phosphate
receptors 1/3 and Toll-like receptor-4, and downstream signaling through p38/MAPK, protein kinase C, and NF-kB. As
regards pro-osteogenic pathways, sphingosine 1-phosphate induced calcium deposition and the expression of the
calcification markers bone morphogenetic protein-2 and alkaline phosphatase, and enhanced the effect of
lipopolysaccharide, an effect that was partially blocked by inhibition of sphingosine 1-phosphate receptors 3/2 signaling.
In conclusion, the interplay between sphingosine 1-phosphate receptors and Toll-like receptor 4 signaling leads to a
cooperative up-regulation of inflammatory, angiogenic, and osteogenic pathways in aortic valve interstitial cells that seems
relevant to the pathogenesis of aortic stenosis and may allow the inception of new therapeutic approaches.
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Introduction
Calcific aortic stenosis is the most frequent cause of aortic valve
replacement in developed countries [1]. The underlying disease-
driving mechanisms are not fully understood, although the role of
inflammation, lipid accumulation, matrix remodeling, angiogen-
esis, and the renin-angiotensin system has been demonstrated [1],
[2], [3], [4]. After clinical trials showing no significant effects of
lipid lowering statins [5], invasive valve replacement or transcath-
eter aortic valve implantation are the only effective therapies [4],
[6].
Sphingosine 1-phosphate (S1P), a bioactive lipid mediator
synthesized by platelets, endothelial cells and erythrocytes [7],
[8], regulates various cellular functions, including proliferation,
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survival, migration, adhesion, and inflammation [8], and plays a
role in the cardiovascular system [9], [10]. S1P is mainly
associated to lipoproteins and albumin and its concentrations are
around mM in plasma and nM in tissues. S1P can either act as an
intracellular second messenger or on the cell surface in an
autocrine or paracrine manner by binding to G protein-coupled
receptors known as S1P1-5, which generate multiple signals and a
fine-tuning of specific responses [8], [11]. S1P receptors are widely
expressed in the cardiovascular system, where divergent roles have
been reported, including pro- and anti-atherogenic effects [9],
[10], cardioprotection [10], [12], [13], and cardiac fibrosis [14].
Toll-like receptors (TLRs) are innate immune receptors
involved in the detection of molecular patterns present in
pathogens and endogenous molecules released upon cell damage
and necrosis [15]. Increasing evidence has shown the involvement
of TLRs in the homeostasis and the pathology of the cardiovas-
cular system [16], [17], mainly regarding TLR4, the receptor for
the lypopolysaccharide (LPS) present in Gram-negative bacteria,
and TLR2, the sensor for bacterial lipoproteins and lipoteichoic
acid [15]. Recent reports have demonstrated a connection
between TLRs and aortic stenosis, as TLR2/4/3 activation
promote pro-inflammatory and pro-osteogenic responses in
human aortic valve interstitial cells (AVIC) [18], [19].
Given the prominence of lipid accumulation and inflammatory
changes in aortic stenosis, and S1P involvement in cardiovascular
pathophysiology, the role of S1P in the pro-inflammatory/pro-
osteogenic responses was investigated in AVIC from stenotic and
non-stenotic valves, and compared to valve interstitial cells from
pulmonary valves (PVIC). Our data demonstrate a synergy
between S1P and LPS at a p38 MAPK-dependent signaling step
that enhances pro-inflammatory and pro-osteogenic events in
interstitial cells from the aortic valve and may be relevant to the
pathogenesis of the disease.
Materials and Methods
Ethics Statement
The Review Board from the Hospital Clı´nico Universitario de
Valladolid approved the study, which complies with the Declara-
tion of Helsinki. All patients gave written informed consent prior
to surgery, following a procedure approved by the Ethics
Committee from the Hospital.
Cell Isolation, Culture, and Characterization
The study included 15 explanted heart valves from patients with
degenerative severe aortic stenosis (11 males/4 females, 7467
years). Aortic valve area was 0.760.2 cm2, peak gradient
78619 mmHg and mean gradient 55613 mmHg. In addition,
15 aortic valves and 15 pulmonary valves from transplant
recipients with valve disease excluded by echocardiography (12
males/3 females, 59610 years) were studied. Diagnosis and
indications for valve replacement and heart transplantation were
performed following European guidelines. Interstitial cells from
aortic and pulmonary valves were isolated using sequential
collagenase digestion, characterized with a-SM-actin staining,
and cultured as described [18], [19], [20]. Three types of cultured
interstitial cells were investigated, namely stenotic AVIC (from
stenotic aortic valve), control AVIC (from non-stenotic aortic
valve), and control PVIC (from non-stenotic pulmonary valve). In
culture, more than 90% of stenotic AVIC, control AVIC, and
control PVIC stained positively for a-SM-actin, consistent with a
myofibroblast phenotype in the three cell types used for the study
(Figure S1).
Real-time RT-PCR Analysis
First-strand cDNA was synthesized from total RNA by the
reverse transcription reaction, and later amplified by PCR using
primer sequences for human S1P receptors, as described [19],
[21]. b-actin was used as a housekeeping gene to assess the relative
abundance of mRNA. Quantification of the mRNA levels was
performed by using the Delta Delta Ct method, where Ct is the
cycle threshold value. The Ct of the sample was normalized to the
Ct of b-actin, and later normalized to the value of the sample with
the lowest expression.
Cytokine Expression Analysis by Antibody Arrays and
ELISA
Cells were stimulated for 12 h with the indicated ligand, S1P or
LPS from E. coli type 0111:B4 (Sigma, St. Louis, MO).
Supernatants were analyzed with Human Cytokine Antibody
Array 5 (RayBiotech, Norcross, GA), as described [19]. Cytokines
analyzed include: ENA-78, G-CSF, GM-CSF, GRO, GRO alpha,
I-309, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-10, IL-12 p40/p70, IL-13, IL-15, IFN-gamma, MCP-1,
MCP-2, MCP-3, M-CSF, MDC, MIG, MIP-1 beta, MIP-1 delta,
RANTES, SCF, SDF-1, TARC, TGF beta 1, TNF alpha, TNF
beta, EGF, IGF-1, Angiogenin, Oncostatin M, Thrombopoietin,
VEGF-A, PDGF-BB, Leptin, BDNF, BLC, Ck beta 8-1, Eotaxin-
1, Eotaxin-2, Eotaxin-3, FGF-4, FGF-6, FGF-7, FGF-9, Flt-3
ligand, Fractalkine, GCP-2, GDNF, HGF, IGFBP-1, IGFBP-2,
IGFBP-3, IGFBP-4, IL-16, IP-10, LIF, Light, MCP-4, MIF, MIP-
3 alpha, NAP-2, NT-3, NT-4, Osteopontin, Osteoprotegerin,
PARC, PLGF, TGF beta 2, TGF beta 3, TIMP-1, and TIMP-2.
Secretion of IL-6, IL-8, PGE2, the soluble form of the intercellular
adhesion molecule 1 (ICAM-1) and vascular endothelial growth
factor (VEGF)-A was evaluated by immunoassay kits following the
manufacturer’s protocol (GE-Healthcare, Buckinghamshire, UK;
RayBiotech, Norcross, GA). Absorbance was measured using a
microplate reader Versamax (Molecular Devices, Sunnyvale, CA).
Immunoblotting for the Detection of Pro-Inflammatory
and Pro-Osteogenic Molecules
Cells were activated with S1P and/or LPS for the indicated
times. Lysates were analyzed by Western blot using antibodies
against human cyclooxygenase-2 (COX-2) and ICAM-1, and the
phosphorylated forms of NF-kB-p65 and MAPK. An anti-b-
tubulin antibody was used as a load control, as described [19].
Bone morphogenetic protein (BMP)-2 detection was performed as
reported [18]. In pharmacological studies, cells were pre-treated
for 30 min with either S1P receptors antagonists W146 (Cayman
Chem., Ann Arbor, MI); VPC 23019 (Avanti Polar Lipids,
Alabaster, AL); JTE-013 (Tocris, Bristol, UK); suramin (Biomol,
Santa Fe, NM), or TLR4 signaling antagonists CLI-095 (Invivo-
Gen, San Diego, CA); CAY10614 (Cayman Chem., Ann Arbor,
MI) or signaling cascades inhibitors NF-kB SN50, ALLN,
SB203580, and GF109203X (Calbiochem, Darmstadt, Germany);
PD98059 (Tocris, Bristol, UK); pertussis toxin (PTX) and
SP600125 (Sigma, St. Louis, MO).
siRNA Interference
Cells were transfected with a liposome-base reagent Dharmafect
(Dharmacon, Lafayette, CO) following manufacturer’s guidelines
as described [18]. Briefly, 100 nM of siRNA, resuspended in Opti-
MEM, were mixed with the Dharmafect reagent to obtain RNA-
liposome conjugates, and later incubated with cells for 24 h.
siRNA duplexes for S1P receptor silencing were the validated
siRNA duplexes specific for S1P human receptors, and a negative
S1P Receptor-TLR4 Cooperation in AVIC
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silencer RNA control (Ambion, Austin, TX): S1P1 (#4143,
#145848), S1P2 (#45076, #44984), and S1P3 (#1959, #1875).
Real-time PCR was performed to confirm S1P receptors knock-
down after 24 h of transfection, as described above. The degree of
inhibition rated from 50-90% for S1P1, 50% for S1P2, and 70%
for S1P3. Transfected cells were activated and ICAM-1 and COX-
2 were analyzed by Western blot.
In Vitro Calcification, and Quantification of Calcium
Deposition and Alkaline Phosphatase (ALP) Activity
For calcification experiments, cells were cultured in condition-
ing medium (M199 supplemented with 10 mmol/l b-glycerophos-
phate, 10 nmol/l vitamin D3, and 10 nmol/l dexamethasone), as
described [19], and stimulated with the indicated agonists or
vehicle every three days. Inhibitors were incubated 1h before the
stimulation. For the quantification of calcium deposition, cells
were stimulated for 25-27 days, and later decalcified with 0.6M
HCl for 24 h. The calcium levels were determined using a calcium
colorimetric assay Kit (Biovision Inc., Milpitas, CA) based on the
o-cresolphtalein complexone method, as described [22]. To
evaluate ALP expression, after 17-19 days of stimulation, cells
were fixed with p-formaldehyde, stained with the ALP blue kit as
previously described [19]. For measuring ALP activity, cells were
lysed and the enzymatic activity was evaluated using a fluoromet-
ric assay kit (Abcam, Cambridge, UK), as described [19].
Statistical Analysis
To analyze the effect of one factor (i.e. treatment), data were
analyzed by a One way-ANOVA with the Tukey posthoc test
using GraphPad Prism version 6 (San Diego, CA); in the case of
one factor and 2 levels, a t test was performed. To analyze the
effect of two factors (i.e. cell x treatment, time x treatment; cell x
treatment at time 10 min), data were analyzed by Two-way
ANOVA with the LSD Fisher posthoc test. To analyze the effect
of three factors (cell x treatment x time), data were analyzed by a
Three-way ANOVA using Statgraphics Centurion XVI 16.2.04
(StatPoint Technologies, Inc. USA; Warrenton, VA). Statistic
analysis is detailed in Table S1. Differences were considered
statistically significant for a p,0.05.
Results
S1P Induces Pro-Inflammatory Molecule Expression in
AVICs
Quantitative RT-PCR experiments revealed S1P receptor
expression in AVIC, being S1P2/3 the most abundant ones
Figure 1. S1P induces pro-inflammatory molecules in AVICs. A) S1P receptor expression in control and stenotic AVICs (mean 6 SEM of the
relative mRNA levels normalized to b-actin, n = 7–10), was assessed by quantitative RT-PCR. B–C) 1 mM S1P induced cytokine secretion, as observed in
antibody arrays and ELISA assays (representative of n = 4, 12 h). Squares indicate positive controls; arrows, constitutive cytokines; ovals, S1P-induced
cytokines. D–E) Comparison of S1P-mediated induction of COX-2 expression (mean 6 SEM, n = 8–12, 1 mM S1P) and PGE2 secretion (mean 6 SEM,
n = 4–5). ELISA data, expressed as pg, were normalized to the cell protein content (mg). *p,0.05. White bars indicate control AVIC; black bars, stenotic
AVIC. Gro indicates growth-regulated oncogene a, b, and c; MCP-1, monocyte chemotactic protein-1; R, resting.
doi:10.1371/journal.pone.0109081.g001
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(Figure 1A). No differences at the mRNA level were observed
between cells from control and stenotic valves (Figure 1A).
Exposure of control AVIC to S1P promoted the secretion of
several pro-inflammatory cytokines (i.e. IL-6, IL-8, Gro, monocyte
chemoattractant protein (MCP)-1), as observed in a cytokine
antibody array (Figure 1B), and quantified by ELISA (Figure 1C).
Additionally, a dose-dependent induction of COX-2 by S1P was
observed by Western blot analysis (Figure 1D). Interestingly, the
up-regulation of COX-2 and of its predominant product PGE2
were more prominent in stenotic than in control AVICs
(Figures 1D-E), thus suggesting that AVIC from stenotic valves
display a lasting enhanced capacity to produce lipid inflammatory
mediators in response to S1P. Together, these data show a S1P-
mediated pro-inflammatory phenotype in AVIC.
Synergy between S1P and LPS Promotes a Marked
Pro-Inflammatory and Pro-Angiogenic Phenotype in
AVIC, with a More Significant Effect in Stenotic AVIC
In light of a previous study demonstrating TLR2-S1P receptors
negative crosstalk in human macrophages [21], we sought to
investigate the potential interaction of S1P and LPS. In control
AVICs, S1P and LPS induced the expression of pro-inflammatory
molecules such as COX-2 and the adhesion molecule ICAM-1
after 8–24 h (Figure 2A). Strikingly, cell exposure to S1P+LPS
induced a remarkable up-regulation of COX-2 and ICAM-1
expression (Figure 2A). The cooperative effect was dose-depen-
dent and observed in the range 1–0.01 mM of S1P (Figure 2B) and
1–0.1 mg/ml of LPS (Figure 2C). The effect showed the features of
a synergistic cooperation between S1P and LPS, because it was
higher than the sum of the effect of either ligand (Figure 2D).
Strikingly, the cooperative effect on COX-2 and ICAM-1 up-
regulation was statistically significantly higher in AVICs from
stenotic than control valves (Figure 2D). Conversely, treatment
with S1P plus the TLR2/TLR1 ligand Pam3CSK4 showed no
synergistic induction of COX-2 and ICAM-1 (Figure 2E),
consistent with the low TLR2 expression reported in AVICs
[18], [19], and arguing for a TLR4-specific effect. Interestingly,
when comparing AVIC and PVIC isolated from the same patient,
the up-regulation of COX-2 and ICAM-1 was significantly higher
Figure 2. S1P cooperates with LPS to up-regulate pro-inflammatory molecules. A) Representative immunoblots show the kinetics of COX-2
and ICAM-1 induction upon activation in control AVIC (n = 8). B–C) Dose-dependent effect (n = 3, 12 h). D) Immunoblots with densitometry data
normalized to b-tubulin levels (mean 6 SEM, n= 10 pairs of control-stenotic AVICs activated for 12 h and processed in the same blot) revealed a
stronger synergistic effect in stenotic than in control AVICs. E) Representative immunoblots of at least 5 experiments show no cooperative effect
between S1P and Pam3CSK4 in stenotic AVICs. F) Immunoblots with densitometry data (mean 6 SEM, n = 8 pairs of AVIC-PVIC from the same heart
processed in the same blot), demonstrate a higher effect in AVIC than in PVIC. White bars indicate control AVIC; black bars, stenotic AVIC; gray bars,
PVIC. L indicates 1 mg/ml LPS; Pam/P, 100 ng/ml Pam3CSK4; S, 1 mM S1P. #p,0.05 for S1P+LPS vs. S1P and LPS;*p,0.05 for the indicated pair.
doi:10.1371/journal.pone.0109081.g002
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in cells from aortic than from pulmonary valves (Figure 2F), which
rarely have stenosis and have a lower TLR4 expression [18].
In agreement with COX-2 up-regulation, S1P+LPS, but not
S1P+Pam3CSK4, cooperated to induce PGE2 secretion in AVICs
(Figure 3A), being the effect statistically significantly higher in cells
from stenotic than from control valves (Figures 3A–B). Addition-
ally, S1P cooperated with LPS to increase IL-6 secretion, being the
induction statistically significantly higher in stenotic than in
control AVICs (Figure 3C). Since the presence of the angiogenic
mediator VEGF-A has been reported in stenotic aortic valves [3],
[23] and angiogenesis is known to be co-dependent with chronic
inflammation in several diseases [24], the induction of VEGF-A
was explored. Interestingly, S1P, known to induce angiogenesis,
cooperated with LPS to promote a statistically significant secretion
of VEGF-A by stenotic AVIC, while no significant effects were
observed in control AVIC (Figure 3D). Altogether, data suggest
that S1P and LPS cooperate to induce a marked pro-inflammatory
and pro-angiogenic phenotype in human AVICs, with a more
significant effect in cells from stenotic valves and lower in cells
from pulmonary valves.
S1P and LPS Cooperate to Induce the Secretion of the
Soluble Form of ICAM-1 (sICAM-1)
sICAM-1, which has been associated with the severity and
prevalence of the calcification in the aortic valve disease in the
Multi-Ethnic Study of Atherosclerosis (MESA) [25], was evaluated
by ELISA. sICAM-1 was detected in the supernatants of LPS-
activated AVICs, and its levels increased synergistically in the
presence of S1P (Figure 3E), thus agreeing with ICAM-1 up-
regulation (Figure 2D). Moreover, the effect was statistically
significantly higher in control than in stenotic AVIC (Figure 3E).
Conversely, treatment with S1P+Pam3CSK4 showed no synergis-
tic induction of sICAM-1 in stenotic AVIC (Figure 3E), arguing
for a TLR4-specific effect. Together, the data demonstrate that
S1P exacerbates LPS-mediated release of the calcification
biomarker sICAM-1 by AVICs.
S1P Receptors and Pro-Inflammatory Routes Involved in
the Synergistic Effect with TLR4
Synergistic effects between S1P and LPS on COX-2 and
ICAM-1 up-regulation were inhibited by pre-treatment with
suramin, a S1P3 antagonist, W146, a S1P1 antagonist, PTX,
which blocks S1P1-3 signaling (Figure 4A), and by knocking down
S1P1/3 expression using a siRNA technique (Figure S2 and
Figure 4B), but not by the S1P2 antagonist JTE-013 (Figure 4A).
Synergy with LPS was mimicked by FTY720, a S1P analogue that
binds to all S1P receptors but S1P2 (Figure 4C). Additionally, the
synergistic effect on sICAM-1 was also sensitive to PTX and
suramin (Figure 4D). Moreover, COX-2 and ICAM-1 up-
regulation was abrogated by blocking the LPS/TLR4 route with
CAY10614 and CLI-095, respectively (Figure 4E).
The analysis of intracellular signaling revealed that AVIC
exposure to S1P+LPS leads to the early activation of NF-kB and
MAPK routes (Figures 5A–B). Interestingly, treatment with S1P+
LPS induced the phosphorylation of p38, but not NF-kB, ERK, or
JNK, in a synergistic manner, since p38 phosphorylation was
higher that the obtained by the sum of the effect of each ligand
alone (Figures 5A–B), thus suggesting that the p38/MAPK
pathway might be a cross-road signaling point. When the effect
on p38 activation was tested in control AVIC and PVIC from the
same patient, control AVIC, but not PVIC, showed a cooperation
effect with S1P+LPS (Figure 5C). In order to compare data from
the different cell types, data was expressed as fold induction of p38
phosphorylated as compared to t = 0 (Figure 5D). As shown in
Figure 3. S1P cooperates with LPS to induce the secretion of pro-inflammatory and pro-angiogenic molecules. Supernatants from cells
treated with the indicated ligands as in Figure 2 were analyzed by ELISA. Data are expressed as pg/mg cell protein (mean6 SEM). A) Kinetics of PGE2
secretion in control and stenotic AVIC, n = 4–5. B) PGE2 secretion data from A at 12 h, mean 6 SEM, n = 4–5. C) IL-6 secretion data at 12 h,
representative of 4 independent experiments. D) VEGF secretion data at 12 h, mean 6 SEM, n = 6. E) sICAM-1 secretion data, mean 6 SEM, n = 5–10.)
Abbreviations were as in Figure 2; color bars, as indicated in the corresponding panel. *p,0.05; #p,0.05 for S1P+LPS vs. LPS and S1P.
doi:10.1371/journal.pone.0109081.g003
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Figure 5D, the cooperation effect of S1P+LPS on p38 activation
was statistically higher in stenotic than in control valve cells and, in
addition the induction was lower in cells from pulmonary than
aortic valves (Figure 5D). Differences might account for their
different inflammatory responsiveness.
As to the induction of pro-inflammatory molecules, and
consistent with the signaling analysis data (Figures 5A–B), the
p38/MAPK inhibitor SB203580 blocked the synergistic up-
regulation of COX-2 and ICAM-1 (Figures 6A–B) as well as
sICAM-1 secretion (Figure 6C). The synergistic effect on COX-2
and ICAM-1 was inhibited by the PKC antagonist GF109203X
(Figures 6A-B), which agrees with the involvement of this kinase
upstream of p38 MAPK. In addition, NF-kB-SN50, which
prevents activation of the pro-inflammatory gene regulator NF-
kB, inhibited the S1P+LPS-mediated up-regulation of COX-2 and
ICAM-1 (Figures 6A–B) and sICAM-1 secretion (Figure 6C), thus
indicating a role of the NF-kB route. The effect on ICAM-1 and
sICAM-1 induction was also significantly reduced by the MEK
inhibitor PD98059 (Figures 6A–B). Altogether, these results
demonstrate the involvement of several S1P receptors and pro-
inflammatory cascades, mainly involving p38/MAPK, in the
synergistic effects with TLR4.
S1P and LPS Cooperate to Induce the Pro-Osteogenic
Markers BMP-2 and ALP as well as Calcium Deposition
Western blot analysis revealed the S1P-mediated induction of
BMP-2 in control AVICs (Figure 7A), being the effect comparable
to that elicited by LPS, known to up-regulate BMP-2 in AVIC
[18]. Moreover, S1P-mediated induction was higher in AVIC than
PVIC from the same patient (Figure 7A). Furthermore, S1P
cooperated with LPS to further increase BMP-2 expression in
AVIC (Figure 7A).
In in vitro calcification studies S1P induced calcium deposition,
and cooperated with LPS to further increase calcium deposits in
control AVIC (Figure 7B). In addition, S1P induced cell aggre-
gation and ALP expression in control AVIC (Figure 7C), an effect
which was similar to that elicited by LPS. Moreover, S1P+LPS
further increased ALP expression (Figure 7C) and ALP activity
(Figure 7D–E) in control AVIC. Additionally, calcium content
(Figure 7B) and ALP activity up-regulation (Figures 7D–E) were
significantly lower in PVICs than in AVICs isolated from the same
patient. The cooperative effect on ALP activity was significantly
inhibited by the S1P2 antagonist JTE-013 and to a lesser extent by
the S1P3 antagonist suramin, by VPC23019, a S1P1/3 antagonist,
and was PTX-sensitive (Figure 7F), thus suggesting the involve-
ment of S1P2/3 subtype receptors. The cooperative effect was also
inhibited by NF-kB-SN50 and the MEK inhibitor PD98059
Figure 4. Receptors involved in the cooperative effect. AVICs were pre-treated with the indicated drugs, activated for 12 h, and cell lysates
and supernatants were analyzed by Western blot and ELISA, respectively. A) Representative immunoblots with densitometry data demonstrate
inhibition of the cooperative effect on COX-2 and ICAM-1 expression (100% value) using S1P1/3 antagonists (n = 6–12). B) Silencing S1P1/3 attenuated
the cooperative effect (n = 3 control AVIC). Scramble, siRNA control; vehicle, 0.1% DEPC. C) Immunoblots showed cooperation between FTY720 and
LPS (n = 3). D) ELISA quantification of sICAM-1 levels show inhibition by S1P1/3 antagonists (n = 6–10). E) Immunoblots demonstrate inhibition of the
cooperative effect by TLR4 antagonists (n = 3). Cay indicates 5 mM CAY10614; CLI, 3 mM CLI-095; FTY, 1 mM FTY720; JTE, 10 mM JTE-013; S+L, S1P+LPS;
PTX, 100 ng/ml pertussis toxin; R, resting; Sur, 10 mM suramin; W146, 10 mM W146. *p,0.05 vs. S1P+LPS.
doi:10.1371/journal.pone.0109081.g004
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(Figure 7G), thus indicating the involvement of the NF-kB and
ERK/MAPK routes. Together, these data demonstrate that S1P
induces in vitro calcification and intensifies the LPS-induced pro-
osteogenic phenotype in AVICs.
Discussion
The present data disclose the role of S1P on the induction of
inflammation and osteogenesis in human AVICs, and support the
relevance of a two-signal paradigm leading to the induction of
enhanced responses, because S1P increases the activity of the
LPS/TLR4 route. Since the synergistic effects are significantly
higher in AVICs from stenotic than control valves and lower in
PVIC, and can be blocked with S1P receptor and TLR4
antagonists, the S1P receptors-TLR4 interplay might have
potential long-term pathophysiologically relevant consequences
and offers new molecular targets for aortic stenosis treatment.
Aortic valves might be exposed to S1P originated from blood
and vascular cell sources, i.e. endothelial cells activated by
physiological fluid shear-stress, platelet activation/aggregation
occurring in active cardiovascular disease states, and erythrocytes
[7], [8]. Also, S1P is associated with lipoproteins, which are
present in stenotic aortic valves [2]. Our study shows that AVIC
mainly express S1P2-3, as compared to predominant subtypes
S1P1-3 in the heart [10], making it likely that, the distinct cell-
dependent expression could account for differential response to
S1P. Additionally, our data shows that S1P up-regulates several
chemokines involved in the recruitment of inflammatory cells like
IL-8, Gro, and MCP-1, and cytokines like IL-6, being the cytokine
profile similar to the described for LPS in a previous study [19].
Moreover, S1P induces COX-2 expression and PGE2 secretion in
AVICs, arguing for a potential role of eicosanoids in the
pathogenesis of aortic stenosis. Consistent with this concept,
recent data have shown the up-regulation of the 5-lipoxygenase
pathway in human aortic valves with severe stenosis, and the
Figure 5. Several signaling cascades, mainly p38/MAPK, are involved in the cooperative effect. A–B) Cell lysates from activated stenotic
AVIC were analyzed for the early phosphorylation of NF-kB and MAP kinases. Representative immunoblots and densitometry data show synergistic
activation of p38 by S1P+LPS (n = 6). Sample at t = 0 was run in both gels for comparison purposes. C) Representative immunoblots of p38
phosphorylation in AVIC and PVIC from the same patient processed in parallel are shown. D) Densitometry data is expressed as the fold induction of
p-p38 relative to resting values (t = 0) using data previously normalized to the reference gene, b-tubulin (mean 6 SEM, n = 5–7). Color bars, as in
Figure 2. *p,0.05; #p,0.05 for S1P+LPS vs. LPS and S1P (at the same time point).
doi:10.1371/journal.pone.0109081.g005
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potentially detrimental role of leukotrienes on valvular myofibro-
blasts [26].
These results show that S1P promotes aggregation and
calcification of human AVICs and agree with the reported role
of S1P on osteoimmunology by osteoclast precursor mobilization
and bone homeostasis [27], and with a recent report describing
S1P-mediated contraction and nodule formation in porcine
AVICs [28]. Additionally, oxidized LDL, which contain S1P
[9], [7], has been proposed to have a potential role in the
development of calcific aortic valve disease [29]. Moreover,
sphingosine kinase 1 overexpression has been shown to promote
cardiomyocyte degeneration and fibrosis in vivo [14]. On the
other hand, the S1P/sphingosine kinase axis has a role on
cardioprotection after ischemic injury in cardiac myocytes and ex
vivo murine hearts by acting as an endogenous cardioprotectant
released by ischemic pre- and post-conditioning [13].The diver-
gent roles of S1P on cardiovascular pathophysiology might be
explained by the different subtypes of S1P receptor expressed and
by the distinct signaling routes involved.
An interesting finding outlined in this report is that S1P
exacerbates the LPS/TLR4-induced inflammatory/osteogenic phe-
notype in AVICs. This synergistic induction may have pathophys-
iological relevance given the stronger effect observed in cells from
stenotic as compared to control valves, and in cells from aortic versus
pulmonary valves. In AVIC, integration of TLR and S1P signaling
pathways might dictate the magnitude of the inflammatory response
and contribute to disease. Based on our data, we propose that a two-
signal paradigm best explains a synergistic inflammatory response
leading to calcification in the valvular disease. On this basis, two
signals might be required to activate a robust inflammatory response
in human AVICs: i) exposure to microbial products and/or
endogenous ligands originated by cell damage and necrosis and ii)
stimulation by S1P released from platelet or endothelial or
erythrocytes. Our findings are reminiscent of recent reports
demonstrating S1P receptor-TLR4 cooperation to induce cytokine
production in human gingival epithelial cells [30], and cytokine/
adhesion molecule expression in human endothelial cells [31].
Another report shows that TLR4 and Notch1 pathways crosstalk
increases the inflammatory response in stenotic AVIC [32]. An
important aspect is the cell-specificity of the TLRs-S1P receptor
crosstalk. In stark contrast, S1P1/2 negatively regulates TLR2-
signaling in human monocytes/macrophages and this could explain
some S1P-mediated anti-atherogenic properties [21], thus stressing
of its dependence on the cell context and the microenvironment.
Interestingly, S1P and LPS cooperate to induce the secretion of
the pro-angiogenic factor VEGF-A in stenotic but not in control
AVIC. These results are consistent with a recent report proposing
that mast cells and myofibroblasts may promote valvular
neovascularisation by modifying the angiogenic/anti-angiogenic
factor balance [33]. Additionally, the differences between control
and stenotic AVICs are consistent with the reported faster
formation of angiogenic sprouts in stenotic than in control valves
[34]. Moreover, we observed that S1P and LPS cooperate to
induce the secretion of the inflammatory mediators PGE2 and IL-
6, which have been reported to induce VEGF [35]. In addition,
IL-6 has been reported to induce endothelial cell migration [36], a
crucial step in angiogenesis.
Cooperation of S1P and LPS on the induction of the pro-
osteogenic and calcification biomarkers supports the concept of
inflammation-dependent development of calcific aortic valve
disease emerging from in vitro, clinical studies, and multimodal
molecular imaging studies [3], [37], [26]. Calcification is less
frequent in pulmonary than in aortic valves and a mechanical
hypothesis has been proposed to explain those differences in
pathology, since the pulmonary valve leaflets are under a
significantly less severe mechanical stress than aortic valve leaflets
[38]. In favor of an alternative hypothesis is a report emphasizing
that the TLR-mediated pro-inflammatory and pro-osteogenic
phenotype in AVIC is not observed in PVIC [18]. Consistent with
a valve-specific response, the magnitude of the S1P receptor-
TLR4 cooperative effect in PVIC is significantly lower than in
AVIC from the same patient, which provides a molecular
explanation of why stenosis is rarely observed in pulmonary
valves. AVICs have the machinery to fine-tuning inflammatory
responses that may become inappropriate on the face of repeated
pro-inflammatory stimuli, since cells from diseased valves showed
a more robust synergistic effect. A question raised by these findings
Figure 6. Signaling routes implicated in the cooperative effect. A–B) AVIC were pre-treated with the indicated drugs, activated for 12 h, and
analyzed as in Figure 4. Representative immunoblots of AVIC lysates and densitometry data show inhibition of the cooperative effect on COX-2 and
ICAM-1 (100% value) by NF-kB-SN50 and MAPK inhibitors (n = 8). C) Supernatants were analyzed for sICAM-1 as in Figure 3 (n = 6). GF indicates
300 nM GF109203X; PD, 50 mM PD98059; SB, 10 mM SB203580; S+L, S1P+LPS; SN50; 50 mg/mL NF-kB SN50; SP, 10 mM SP600125. *p,0.05 vs. S1P+LPS
(100% value).
doi:10.1371/journal.pone.0109081.g006
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is how inappropriate responses could lead to osteoblastic
differentiation.
In light of our findings, therapeutic interference with S1P
receptor and TLR4 signaling could be a potentially useful strategy
to slow down aortic stenosis progression by avoiding inappropriate
inflammatory responses. Our data demonstrate the involvement of
S1P3/1 in inflammation and S1P2/3 in calcification responses in
interplay with TLR4. Recently, it has been proposed that S1P3
plays a causal role in atherosclerosis by promoting monocyte/
macrophage recruitment and altering smooth muscle cell behavior
[39], and it seems involved in cardiac myofibroblast differentiation
[40]. S1P2 has been associated with regeneration and fibrosis after
liver [41], and S1P1 has been linked to pulmonary fibrosis [42].
The molecular basis of cooperative induction of inflammatory
molecules by S1P and LPS seems to rely on an intersection on the
p38/MAPK signaling route. The different levels of induction of
p38 activation might account for the differences in the pro-
inflammatory and pro-osteogenic responses observed in stenotic
versus control AVIC, and in aortic versus pulmonary valve cells.
The p38/MAPK signaling route has been implicated in cardiac
Figure 7. S1P cooperates with LPS to up-regulate pro-osteogenic markers and calcium deposition. A) AVIC and PVIC from the same
patient were activated as in Figure 2 for 48 h and analyzed with a BMP-2 antibody. Immunoblots and densitometry data are representative of at least
3 pairs of AVIC-PVIC processed in the same blot. Data are expressed as fold induction of BMP2, normalized to b-tubulin, as compared to resting
conditions (mean 6 SEM, n= 6 pairs of AVIC-PVIC). B–G) AVIC and PVIC from the same patient were treated with conditioning media (CM) in the
presence of 1 mg/ml LPS, 0.1 mM S1P or vehicle as indicated in Methods. B) Calcium deposition expressed as mg Ca2+/mg protein is shown (mean 6
SEM, n = 3 pairs of AVIC and PVIC with a total of 11 replicates). C) ALP blue staining of control AVIC (n = 3). D) Representative ALP data is expressed as
nmol/mg.h. E) Data from control AVIC and PVIC are expressed as fold increase of ALP activity (mean 6 SEM, n = 12 AVIC, n = 8 PVIC) relative to data
with growth media. F–G). ALP activity in control AVIC pre-treated with the indicated drugs before activation (n = 5–9) Drug concentrations were as in
Figures 4–5. M indicates M199, growth media; white bars, AVIC; gray bars, PVIC. *p,0.05; #p,0.05 for S1P+LPS vs. LPS and S1P.
doi:10.1371/journal.pone.0109081.g007
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hypertrophy, ischemic injury, and heart failure [43]. Moreover,
data demonstrate that PKC, an upstream kinase that activates
TAK1 and the p38 kinase activator MKK3, seems to be involved
in the effect. The TAK1-MKK3/6-p38MAPK signaling axis has
been reported to be important for TGF-beta-related cardiac
hypertrophy [44]. Furthermore, our data demonstrate the
involvement of NF-kB, in particular the p50/p65 heterodimers,
in the S1P receptor-TLR4 cooperative effect on inflammation/
osteogenesis. Interestingly, whereas the p38/MAPK seems impli-
cated in the synergistic induction of pro-inflammatory molecules,
the ERK/MAPK is involved in the cooperative effect on
osteogenesis, consistent with its reported role in AVIC calcification
[45].
In conclusion, these data disclose S1P as a novel inducer of
inflammation and calcification of human AVIC. Moreover, the
pair S1P receptors-TLR4 may be potential targets for aortic
stenosis treatment since S1P cooperates with LPS to induce
synergistic inflammatory, angiogenic, and osteogenic responses.
Supporting Information
Figure S1 Characterization of AVICs from stenotic and
control aortic valves and PVIC from control pulmonary
valves. Cells were labeled with a FITC-conjugated antibody
against a-SM-actin followed by DAPI staining to visualize nuclei,
and later analyzed by fluorescence microcopy (Nikon ECLIPSE
90i fluorescence microscope coupled to a Nikon DS-Ri1 camera).
Representative images of cells correspond to stenotic (left panel)
and control aortic valve cells (central panel), and to control
pulmonary valve cells (right panel), being control AVIC and
control PVIC isolated from the same patient. Images were
obtained using Image J software. In green are shown images from
FITC staining (positively labeled with a-SM-actin); in blue are
images from DAPI staining (nuclei). More than 95% cells in
culture were myofibroblast. No apparent morphological differ-
ences in cells explanted from control and stenotic valves were
observed.
(TIF)
Figure S2 Knock-down of S1P receptor mRNA expres-
sion by siRNA technique. Cells were transfected with RNA
duplex that inhibited mRNA expression of the indicated S1P
receptor genes, or a siRNA control (scramble) or the vehicle. Plots
represent the quantitative PCR profiles in comparison with the
housekeeper gene b-actin. Images are representative of 3
independent experiments.
(EPS)
Table S1 Summary of Statistical Analysis. Detailed
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